Trial Profile

A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vamorolone (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions; Therapeutic Use
Sponsors ReveraGen BioPharma

Most Recent Events

28 Apr 2021 Results (new clinical data of 2.5-year treatment outcome) presented in a Santhera Pharmaceuticals media release.
22 Sep 2020 According to a Santhera Pharmaceuticals media release, this trial is conducted by the Cooperative International Neuromuscular Research Group (CINRG).
22 Sep 2020 Results presented in the Santhera Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com